Role of oxidative stress in diabetic complications: A new perspective on an old paradigm

Diabetes

Volumn 48, Issue 1, 1999, Pages 1-9

  Baynes, John W ^a   Thorpe, Suzanne R ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CARBOHYDRATE; CARBONYL DERIVATIVE; COLLAGEN; DEOXYGLUCOSE; LIPID; PROTEIN;

ATHEROSCLEROSIS; CHRONIC DISEASE; COLLAGEN SYNTHESIS; DIABETES MELLITUS; LIPID OXIDATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; DIABETES COMPLICATIONS; HUMANS; MODELS, BIOLOGICAL; OXIDATIVE STRESS;

EID: 0032913309     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.48.1.1     Document Type: Review

References (91)

1. The DCCT Research Group: The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N Engl J Med 329:977-986, 1993
2. Brownlee M: Advanced protein glycosylation in diabetes and aging. Ann Rev Med 46:223-234, 1996
3. Vlassara H: Recent progress in advanced glycation end products and diabetic complications. Diabetes 46 (Suppl. 2): S19-S25, 1997
4. Hotta N: New approaches for treatment in diabetes: aldose reductase inhibitors. Biomed Pharmacother 49:232-243, 1995
5. Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412, 1991
6. Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications. Diabetes Care 19:257-267, 1996
7. Baynes JW, Thorpe SR: The role of oxidative stress in diabetic complications. Curr Opin Endocrinol 3:277-284, 1997
8. Van Dam PS, Van Asbeck BS, Erkelens BW, Marx JJM, Gispen W-H, Bravenboer B: The role of oxidative stress in neuropathy and other diabetic complications. Diabetes Metab Rev 11:181-192, 1995
9. Williamson JR, Chang K, Frangos M, Hasan KS, Ido V, Kawamura T, Nyengaard JR, van den Enden M, Kilo C, Tilton RG: Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42:801-813, 1993
10. +, free radicals, and vascular dysfunction in early diabetes mellitus. Diabetologia 40 (Suppl. 2):S115-S117, 1997
11. Cameron NE, Cotter MA: Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 46 (Suppl. 2):S31-S37, 1997
12. Lyons TJ, Jenkins AJ: Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis. Diabetes Rev 5:365-391, 1997
13. Degenhardt TP, Brinkmann-Frye E, Thorpe SR, Baynes JW: Role of carbonyl stress in aging and age-related diseases. In The Maillard Reaction in Foods and Medicine. O'Brien J, Nursten HE, Crabbe MJC, Ames JM, Eds. Royal Society of Chemistry, London, 1998, p. 3-10
14. Witztum JL: Role of modified lipoproteins in diabetic macroangiopathy. Diabetes 46 (Suppl. 2):S112-S114, 1997
15. Lopes-Virella MF, Mironova M, Virella G: LDL-containing immune complexes and atherosclerosis in diabetes. Diabetes Rev 5:410-424, 1997
16. Ishii H, Daisuke K, King GL: Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med 76:21-31, 1998
17. Pfeiffer A, Schatz H: Diabetic microvascular complications and growth factors. Exp Clin Endocrinol Diabetes 103:7-14, 1995
18. Sharma K, Ziyadeh FN: Biochemical events and cytokine interactions linking glucose metabolism to the development of diabetic nephropathy. Sem Nephrol 17:80-92, 1997
19. Wolff SP, Dean RT: Glucose autoxidation and protein modification: the potential role of autoxidative glycosylation in diabetes. Biochem J 245:243-250, 1987
20. Wolff, SP, Jiang ZY, Hunt JV: Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med 10:339-352, 1991
21. Requena JR, Baynes JW: Studies in animal models on the role of glycation and advanced glycation end-products (AGEs) in the pathogenesis of diabetic complications: pitfalls and limitations. In Lessons From Animal Models of Diabetes. Vol. VII. Sima AAF, Ed. Boston, Birkhauser. In press
22. Hamada Y, Araki N, Koh N, Nakamura J, Horiuchi S, Hotta N: Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway. Biochem Biophys Res Commun 228:539-543, 1996
23. Sell DR, Lapolla A, Odetti P, Fogarty J, Monnier VM: Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 41:1286-1292, 1992
24. Beisswenger PJ, Moore LL, Brinck-Johnsen T, Curphey TJ: Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy. J Clin Invest 92:2212-2217, 1993
25. Dyer DG, Dunn JA, Thorpe SR, Baillie KE, Lyons TJ, McCance DR, Baynes JW: Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91:2463-2469, 1993
26. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thorpe SR, Baynes JW, Lyons TJ: Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 91:2470-2478, 1993
27. Wells-Knecht MC, Lyons TJ, McCance DR, Thorpe SR, Baynes JW: Age-dependent accumulation of ortho-tyrosine and methionine sulfoxide in human skin collagen is not increased in diabetes: evidence against a generalized increase in oxidative stress in diabetes. J Clin Invest 100:839-846, 1997
28. Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier J-L, Ogawa S, Kuwabara K, Matsumoto M, Stern D: RAGE: a novel cellular receptor for advanced glycation end-products. Diabetes 45 (Suppl. 3):S77-S80, 1996
29. Araki N, Higashi T, Mori T, Shibayama R, Kawabe Y, Kodama T, Takahashi K, Shichiri M, Horiuchi S: Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. Eur J Biochem 230:408-415, 1995
30. Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, Ueda O, Sakaguchi H, Higashi T, Suzuki T, Takashima Y, Kawabe Y, Cynshi O, Wada Y, Honda M, Kurihara H, Aburatani H, Doi T, Matsumoto A, Azuma S, Noda T, Toyada Y, Itakura H, Yazaki Y, Kodama T: A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 386:292-296, 1997
31. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269:9889-9897, 1994
32. Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P, Tritschler H, Wahl P, Ziegler R, Müller M, Nawroth PP: Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 96:2262-2271, 1997
33. Fu S, Fu M-X, Baynes JW, Thorpe SR, Dean RT: Presence of DOPA and amino acid hydroperoxides in proteins modified with advanced glycation end products (AGEs): amino acid oxidation products as a possible source of oxidative stress induced by AGE-proteins. Biochem J 330:233-239, 1998
34. Wautier J-L, Wautier M-P, Schmidt A-M, Anderson GM, Hori O, Zoukourian C, Capron L, Chappey O, Yan S-D, Brett J, Guillausseau P-J, Stern D: Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci U S A 91:7742-7746, 1994
35. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, Vlassara H: Modification of low-density lipoprotein contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A 91:9441-9445, 1994
36. Miyata T, Fu M-X, Kurokawa K, van Ypersele di Strihou C, Thorpe SR, Baynes JW: Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? Kidney Int 54:1290-1295, 1998
37. Miyata T, Ueda Y, Yoshido A, Sugiyama S, Iida Y, Jadoul M, Maeda K, Kurokawa K, van Ypersele de Strihou C: Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int 51:880-887, 1997
38. Vlassara H, Bucala R: Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Diabetes 45 (Suppl. 3):S65-66, 1996
39. Platt N, Suzuki H, Kurihara Y, Kodama T, Gordon S: Role for the class A macrophage scavenger receptor in the phagocytosis of apoptotic thymocytes in vivo. Proc Natl Acad Sci U S A 93:12456-12460, 1996
40. ε-(carboxymethyl)lysine is a dominant advanced glycation end-product (AGE) antigen in tissue proteins. Biochemistry 34:10872-10878, 1995
41. ε-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 271:9982-9986, 1996
42. Kume S, Takeya M, Mori T, Araki N, Suzuki H, Horiuchi S, Kodama T, Miyauchi T, Takahashi K: Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am J Pathol 147:654-667, 1995
43. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H: Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A 90:6434-6438, 1993
44. Requena JR, Ahmed MU, Fountain CW, Degenhardt TP, Reddy SR, Perez C, Lyons TJ, Jenkins AJ, Baynes JW, Thorpe SR: Carboxymethylethanolamine: a biomarker of phospholipid modification during the Maillard reaction in vivo. J Biol Chem 272:17473-17479, 1997
45. Thorpe SR, Baynes JW: Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging 9:69-77, 1996
46. Sell DR, Monnier VM: End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest 85:380-384, 1990
47. Beckmann JS, Ye YZ, Anderson PG, Chen J, Accavitti MA, Tarpey MM, White CR: Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe-Seyler 375:81-88, 1994
48. Hazen SL, Heinecke JW: 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 99:2075-2081, 1997
49. Finch CE, Cohen DM: Aging, metabolism, and Alzheimer's disease: review and hypotheses. Exp Neurol 143:82-102, 1997
50. Markesbery WR: Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 23:134-147, 1997
51. 2-Microblobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 92:1243-1252, 1993
52. Ando Y, Nyhlin N, Suhr O, Holmgren G, Uchida K, El Sahly M, Yamashita T, Terasaki H, Nakamura M, Uchino M, Ando M: Oxidative stress is found in amyloid deposits in systemic amyloidosis. Biochem Biophys Res Commun 232:497-502, 1997
53. Horie K, Miyata T, Maeda K, Miyata S, Sugiyama S, Sakai H, van Ypersele di Strihou C, Monnier VM, Witztum JL, Kurokawa K: Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. J Clin Invest 100:2995-3004, 1997
54. ε-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 99:457-468, 1997
55. Niwa T, Takeda H, Yoshizumi H, Tatematsu A, Ohara M, Timiyama S, Niimura K: Presence of 3-deoxyglucosone, a potent protein crosslinking intermediate of the Maillard reaction. Biochem Biophys Res Commun 196:837-843, 1993
56. Yamada H, Miyata S, Igaki N, Yatabe H, Miyauchi Y, Ohara T, Sakai M, Shoda H, Oimomi M, Kasuga M: Increase in 3-deoxyglucosone levels in diabetic rat plasma. J Biol Chem 269:20275-20280, 1994
57. Niwa T, Takeda N, Miyazaki T, Yoshizumi H, Tatematsu A, Maeda M, Ohara S, Tomiyama S, Kiimura K: Elevated serum levels of 3-deoxyglucosone, a potent crosslinking intermediate of the Maillard reaction, in uremic serum. Nephron 69:438-433, 1995
58. Hamada Y, Nakamura J, Fujisawa H, Yago H, Nakashima E, Koh N, Hotta N: Effects of glycemic control on plasma 3-deoxyglucosone levels in NIDDM patients. Diabetes Care 20:1466-1469, 1997
59. Niwa T, Katsuzaki T, Miyazaki S, Miyazaki T, Ishizaki Y, Hayase F, Tatemichi N, Takei Y: Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest 99:1272-1280, 1997
60. Niwa T, Miyazaki T, Katsuzaki T, Tatemichi N, Takei, Y: Serum levels of 3-deoxyglucosone and tissue contents of advanced glycation end products are increased in streptozotocin-induced diabetic rats with nephropathy. Nephron 74:580-585, 1996
61. Ledl F, Schleicher E: New aspects of the Maillard reaction in foods and in the human body. Angew Chem Int Ed Engl 29:565-594, 1990
62. Szwergold BS, Kappler F, Brown TR: Identification of fructose-3-phosphate in the lens of diabetic rats. Science 247:451-454, 1990
63. Lal S, Randall WC, Taylor WH, Kappler F, Walker M, Brown TR, Szwergold BS: Fructose-3-phosphate production and polyol pathway metabolism in diabetic rat hearts. Metab Clin Exp 46:1333-1338, 1997
64. Thornalley PJ, Hooper NI, Jennings PE, Florkowski CM, Jones AF, Lunec J, Barnett AH: The human red blood glyoxalase system in diabetes mellitus. Diabetes Res Clin Pract 7:115-120, 1989
65. Nagaraj RH, Shipanova IN, Faust FM: Protein crosslinking by the Maillard reaction: isolation, characterization, and in vivo detection of a lysine-lysine crosslink derived from methylglyoxal. J Biol Chem 271:19339-19345, 1996
66. Shamsi FA, Partal A, Sady C, Glomb MA, Nagaraj RH: Immunological evidence for methylglyoxal-derived modifications in vivo: determination of antigenic epitopes. J Biol Chem 273:6928-6936, 1998
67. Thornalley PJ: Pharmacology of methylglyoxal. Gen Pharmacol 27:565-573, 1996
68. Srivastava S, Chandra A, Bhatnagar A, Srivastava SK, Ansari NH: Lipid peroxidation product 4-hydroxynonenal and its conjugate with GSH are excellent substrates of bovine lens aldose reductase. Biochem Biophys Res Commun 217:741-746, 1995
69. Vander Jagt DL, Robinson B, Taylor KK, Hunsaker LL: Reduction of trioses by NADPH-dependent aldo-keto reductase. J Biol Chem 267:4364-4369, 1992
70. Siems WG, Grune T, Beierl B, Zollner H, Esterbauer H: The metabolism of 4-hydroxynonenal, a lipid peroxidation product, is dependent on tumor age in Ehrlich mouse ascites cells. In Free Radicals in Aging. Emerit I, Chance E, Eds. Basel, Birkhäuser, 1992, p. 124-135
71. Srivastava S, Chandra A, Wang L-F, Seifert WE Jr, DaGue BB, Ansari N, Srivastava SK, Bhatnagar A: Metabolism of the lipid peroxidation product, 4-hydroxy-trans-2-nonenal, in isolated perfused rat heart. J Biol Chem 273:10893-10900, 1998
72. Jellum E: Metabolism of the ketoaldehyde 2-keto-3-deoxyglucosone. Biochim Biophys Acta 165:357-363, 1968
73. Kato H, van Chuyen N, Shinoda t, Sekiya F, Hayase F: Metabolism of 3-deoxyglucosone, an intermediate compound in the Maillard reaction, administered orally or intravenously to rats. Biochim Biophys Acta 1035:71-76, 1990
74. Kanazu T, Shinoda M, Nakayama T, Deyashiki Y, Hara A, Sawada H: Aldehyde reductase is a major protein associated with 3-deoxyglucosone reductase activity in rat, pig and human livers. Biochem J 279:903-906, 1991
75. Kashiwagi A, Nishio Y, Asahina T, Ikebuchi M, Harada N, Tanaka Y, Takahara N, Taki H, Obata T, Hidaka H, Saeki Y, Kikkawa R: Pyruvate improves deleterious effects of high glucose on activation of pentose phosphate pathway and glutathione redox cycle in endothelial cells. Diabetes 46:2088-2095, 1997
76. Baynes JW: Reactive oxygen in the aetiology and complications of diabetes. In Drugs, Diet and Disease, Vol. 2: Mechanistic Approaches to Diabetes. Ioannides C, Ed. London, Pergamon, 1996, p. 203-240
77. Che W, Asahi M, Takahashi M, Kaneto H, Okado A, Higashiyama S, Taniguchi N: Selective induction of heparin-binding epidermal growth factor-like growth factor by methylglyoxal and 3-deoxyglucosone in rat smooth muscle cells: the involvement of reactive oxygen species formation and a possihle implication for atherogenesis in diabetes. J Biol Chem 272:18453-18459, 1997
78. Choudhary D, Chandra D, Kale RK: Influence of methylglyoxal on antioxidant enzymes and oxidative damage. Toxicol Lett 93:141-152, 1997
79. Okado A, Kawasaki Y, Hasuike Y, Takahashi M, Teshima T, Fujii J, Taniguchi N: Induction of apoptotic cell death by methylglyoxal and 3-deoxyglucosone in macrophage-derived cell lines. Biochem Biophys Res Commun 225:219-224, 1996
80. Onorato JM, Thorpe SR, Baynes JW: Immunochemical and ELISA assays for biomarkers of oxidative stress in aging and disease. Ann N Y Acad Sci. In press
81. Wells-Knecht KJ, Brinkmann E, Wells-Knecht MC, Ahmed MU, Zyzak DV, Thorpe SR, Baynes JW: New biomarkers of Maillard reaction damage to proteins. Nephrol Dial Transplant 11 (Suppl. 5):41-47, 1996
82. Requena JR, Fu M-X, Ahmed MU, Jenkins AJ, Lyons TJ, Thorpe SR: Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions. Nephrol Dial Transplant 11 (Suppl 1):48-53, 1996
83. Cogan DG, Donaldson DD: Experimental radiation cataracts: cataracts in the rabbit following single X-ray exposure. Arch Ophthalmol 45:508-518, 1951
84. Hockwin O: Early changes of lens metabolism after X-irradiation. Exp Eye Res 1:422-426, 1962
85. Sell DR, Lane MA, Johnson WA, Masoro EJ, Mock OB, Reiser KM, Fogarty JF, Cutler RG, Ingram DK, Roth GS, Monnier VM: Longevity and the genetic determination of collagen glycoxidation kinetics in mammalian senescence. Proc Natl Acad Sci USA 93:485-490, 1996
86. Picard S, Parthasarathy S, Fruebis J, Witztum JL: Aminoguanidine inhibits oxidative modification of low density lipoprotein and the subsequent increase in uptake by macrophage scavenger receptor. Proc Natl Acad Sci U S A 89:6876-6880, 1992
87. Kochakian M, Manjula BN, Egan JJ: Chronic dosing with aminoguanidine and novel advanced glycosylation end product-formation inhibitors ameliorates cross-linking of tail tendon collagen in STZ-induced diabetic rats. Diabetes 45:1694-1700, 1996
88. Nakamura S, Makita Z, Ishikawa S, Yasumura K, Fujii W, Yanagisawa K, Kawata T, Koike T: Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46:895-899, 1997
89. Booth AA, Khalifah RG, Hudson BG: Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Biochem Biophys Res Commun 220:113-119, 1996
90. Booth AA, Khalifah RG, Todd P, Hudson BG: In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs): novel inhibition of post-Amadori glycation pathways. J Biol Chem 272:5430-5437, 1997
91. Degenhardt TP, Alderson NL, Thorpe SR, Baynes JW: Pyridorin, a post-Amadori inhibitor of advanced glycation reactions, preserves renal function in diabetic rats (Abstract). J Am Soc Nephrol 9 (Suppl. 1):628A, 1998